The recent 64.82% surge in Incannex Healthcare (NASDAQ: IXHL) attracted investors' attention and marked one of the most dramatic moves in the legal cannabis sector in 2025. We are experiencing rapid changes. Clinical Catalyst: IHL-42X and Reposa TestsAt the heart of Incannex's momentum is IHL-42X, the leading drug candidate for IHL-42X, a combination of fixed doses of dronabinol and acetazolamide to treat obstructive sleep apnea (OSA). The phase 2 portion of the global reposa trial, completed in 120 patients in the US, provided pharmacokinetics (PK) data indicating bioavailability comparable to the reference drug. This will allow the program to take…
Author: admin
The rise of Medicare Advantage (MA) has restructured the home care landscape, but has put home health providers in a precarious position, while increasingly unstable for beneficiaries. This is adjusting to increased penetration of MA, with a major change in patient care methods, including care plans adjustments, according to leaders at Lewiston, a Maine-based nonprofit provider and well health partner. Ken Albert, CEO of Andwell Health Partners, said in a recent episode of Home Health Care News' podcasts that MA is rapidly becoming a “failed policy.” Previously known as Androscoggin Home Healthcare + Hospice, Andwell Health Partners offers home health,…
A federal judge has dismissed Humana (NYSE: HUM) lawsuits against the U.S. Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS). The company filed a lawsuit in October 2024, challenging CMS' Medicare Advantage (MA) quality score. Humana claimed that government agencies act “arbitrarly and on a whim” when downgrading their ratings, affecting bonus payments and overall revenue. He also described the program's data and calculations as “dizzy and complicated.” On July 18th, Texas Judge Reed O'Connor ruled that Humana's case was premature as he had not yet obtained the results of the CMS…
The Nursing and Midwifery Council (NMC) has reported record high numbers of disciplinary case screenings, and a further speeding up of its case resolution timeline. The reported improvements in case resolution times come as the regulator continues to face scrutiny about the way it operates. In June this year, the NMC said around 70.4% of fitness to practise (FtP) cases were being resolved within 15 months, representing an increase of around 10 percentage points on July 2023. “We are seeing steady improvements” Lesley Maslen Meanwhile, in May this year, 809 screening decisions were made in what was a new monthly…
Health and social care secretary Wes Streeting has unveiled long-awaited new proposals on regulating NHS managers, including executive-level nurses who sit on trust boards. The proposals, which will be put before parliament next year, will set out the “first steps” to introduce professional standards and regulation for this staff group, the government said “I’m determined to create a culture of honesty and openness in the NHS where whistleblowers are protected” Wes Streeting Currently, NHS managers who are registered clinicians, such as nurses, are subject to their own professional regulators, for example the Nursing and Midwifery Council and General Medical Council.…
OpenEvidence has closed its $210 million Series B funding round at a $3.5 billion valuation as Google Ventures and Kleiner Perkins leads its investments. The Cambridge-based medical AI company has raised over $300 million since its establishment, and today more than 40% of US physicians log in to make clinical decisions every day. The platform operates in more than 10,000 hospitals and medical centers nationwide, with over 65,000 new, verified US clinical doctor registrations each month. In July 2024, OpenEvidence supported consultations from around 358,000 logged in doctors in a month. A year later, the platform will process that volume…
President Donald Trump's trade policy sparked a stir on Wall Street. The president is calling for aggressive tariffs on imported goods in order to bring manufacturing jobs back to the country. There was hope that certain sectors, including healthcare, would be spared, but it turns out that this is not the case. A higher obligation to import can increase the costs of a company, narrowing down margins and revenues, and significantly impairing stock price performance. But despite this threat, there are still health companies worth investing in, including Eli Lilly. (lly 1.33%)) and Novartis (NVS) -0.25%)). Image source: Getty Images.…
In recent years, the global healthcare industry has begun to explore innovative technologies to solve long-standing problems related to patient data security, billing inefficiency and cross-border payments. Among these technologies, cryptocurrency development has gained great traction. As Healthcare Systems aims to modernize the world, integration of blockchain and cryptocurrency solutions is emerging as a practical step forward. This trend is not a fleeting experiment. This is one of the most sensitive and highly regulated industries, and is a strategic response to the demand for safe, efficient and transparent systems.The need for innovation in medical expensesTraditional healthcare payment ecosystems are fragmented,…
Preceptorships for nurses working in adult social care in England should become more widely available from this autumn, thanks to a new package of support being launched by the organisation Skills for Care. The package of support, funded by the body’s Small but Mighty programme, was unveiled on 18 July to mark the one year anniversary of the organisation’s Workforce Strategy for Adult Social Care. “Preceptorship is a vital step in building an effective and sustainable social care nursing workforce” Claire Leenhouwers The support package is designed to help adult social care providers in England put together structured preceptorship programmes…
Premature babies at risk of life-threatening infection can now be protected against the respiratory syncytial virus (RSV) with a single, long-lasting injection available on the NHS for the first time. Health services across the UK are rolling out the drug nirsevimab from late September to provide protection against RSV to around 9,000 high-risk infants and babies born before 32 weeks this year. “This new medication will provide vulnerable infants with their own suit of armour” John Stewart Nirsevimab (Beyfortus), which offers six months protection in a single dose, will replace monthly injections of palivizumab (Synagis) previously offered to a smaller…